JPT has a work force of >50 highly trained and skilled employees. 20 of our co-workers hold a university degree and 15 have a PhD in natural sciences. Over the last 10 years our team has built a substantial know-how in all areas of peptide applications ranging from biomarker discovery and immune monitoring to proteomics, vaccine and drug development.
Dr. Holger Wenschuh (Managing Director)
Dr. Holger Wenschuh has been Managing Director at JPT Peptide Technologies since 2004. Before, he served as Business Unit Manager at Jerini AG and Managing Director at Chemotopix GmbH. Dr. Wenschuh studied Chemistry at the Friedrich-Schiller-University in Jena, Germany, and obtained his PhD in Organic Chemistry at the Institute of Molecular Pharmacology in Berlin, Germany. He worked at the University of Massachusetts and Perseptive Biosystems, USA and from 1995 to 1997, headed the Peptide Unit at the Max-Planck-Institute of Infection Biology in Berlin.
Dr. Wenschuh is author and co-author of numerous publications, co-inventor on several patents and editorial board member of the International Journal of Peptide Research and Therapeutics.
Sean Marett (Managing Director)
Sean Marett has 30 years of international experience in the management of operations, sales and marketing licensing, M&A and new product development.
He has worked for large pharmaceutical companies such as GSK and Pfizer and done contract research, development and manufacturing for companies such as Evotec and NextPharma. He has successfully executed a number of licensing transactions with large pharmaceutical companies, completed large pharmaceutical service deals and negotiated several M&A transactions. Sean Marett is non-executive director of KWS BioTest Ltd and a member of the investment committee of Mann BioInvest Ltd.
Prof. Florian Kern (Head of Immunology)
Prof. Florian Kern has been Head of Immunology at JPT Peptide Technologies since Sep 2015. He has also been Chair of Immunology at Brighton and Sussex Medical School (Universities of Sussex and Brighton, Brighton, UK) since 2006 and is still active in this role. Until 2006 he headed a research group at the Institute for Medical Immunology at Charité Universitätsmedizin Berlin, Campus Mitte, Berlin/Germany. Prof. Kern is also a medically qualified clinical immunologist, and previously was head of the clinical immunology laboratory at Charité Mitte. He studied Medicine at the Universities of Tübingen and Düsseldorf and obtained an MD in Immunology in Düsseldorf in 1993. He later completed his Habilitation at Charité Berlin in 2002 in the field of transplantation monitoring. Prof. Kern has supervised many MD and PhD students in Germany and the UK and has published numerous international research articles with a particular interest in Cytomegalovirus and antigen specific immune responses. He is an editorial board member of Cytometry Part B: Clinical Cytometry.
Dr. Ulf Reimer (Head of Research & Development)
Dr. Ulf Reimer has been Head of Research and Development at JPT since 2009. He studied Biochemistry at Martin-Luther University Halle/Wittenberg. He completed his PhD Thesis in the "Enzymology of Protein Folding" research group at the Max-Planck-Society at Halle/Saale. From 1998 to 2000 he was a postdoctoral researcher in the same group and in the group of Prof. Griesinger at the University of Frankfurt/Main. Later he joined Jerini AG in Berlin, where he started as a scientist. He later took on a managerial role as Director of Computational Chemistry at Jerini AG, in which he was jointly responsible for drug discovery and development.
Dr. Reimer is author and co-author of a numerous publications, and co-inventor on many patents.